{
  "main_header": {
    "sid": 1130126,
    "name": "Astellas Pharma, Inc.",
    "stock_name": "Astellas Pharma, Inc.",
    "full_name": "Astellas Pharma, Inc.",
    "name_url": "stocks-analysis/astellas-pharma-inc",
    "exchange": 121,
    "exchangecode": "TKS",
    "country_id": 23,
    "currency": "JPY",
    "cmp": "2,048.00",
    "chg": 28,
    "chgp": "1.39%",
    "dir": 1,
    "prev_price": "2,020.00",
    "mcapval": "3,078,236.89",
    "mcap": "Large Cap",
    "scripcode": "",
    "symbol": "",
    "ind_name": "Pharmaceuticals & Biotechnology",
    "ind_code": 2305,
    "indexname": "Japan Nikkei 225",
    "isin": "JP3942400007",
    "curr_date": "Dec 11",
    "curr_time": "",
    "bse_nse_vol": "13.28 M",
    "exc_status": "Active",
    "traded_date": "Dec 11, 2025",
    "traded_date_str": "2025 12 11",
    "score": "",
    "scoreText": "",
    "Live": 0,
    "market_time": 0,
    "is_blur": 1,
    "is_blur_class": "blur-registerF-score-header",
    "is_blur_url": "https://www.marketsmojo.com/mojofeed/register?redirect=/stocks-analysis/astellas-pharma-inc-1130126-121&utm_source=Spage_Header_Score",
    "mojoone": {
      "ismore": 0
    }
  },
  "news": {
    "results": [
      {
        "title": "Astellas Pharma, Inc. Shows Strong Financial Growth Amidst Flat Performance",
        "link": "https://www.marketsmojo.com/news/mojo-premium/astellas-pharma-inc-enters-mojo-stocks-strategy-with-strong-financials-3690068",
        "imagepath": "",
        "date": "2025-11-11 16:16:05",
        "description": "<p><strong>Astellas Pharma, Inc.</strong> has reported its financial results for the quarter ending June 2025, revealing a mixed performance characterized by notable growth in key profit metrics despite an overall flat financial performance. The company's operating profit reached an impressive JPY 157,307 MM, marking the highest level recorded, with an operating profit margin of 31.1%. This indicates a strong operational efficiency and profitability for the company during this period.</p>\n\n<p>In addition to the robust operating profit, <strong>Astellas Pharma, Inc.</strong> also reported significant growth in its pre-tax profit, which surged to JPY 92,009 MM, reflecting an impressive year-on-year growth rate of 89.45%. This substantial increase highlights the company's ability to enhance its profitability before tax considerations.</p>\n\n<p>The net profit for the quarter also demonstrated remarkable growth, ..."
      },
      {
        "title": "Astellas Pharma Stock Hits Day Low Amid Price Pressure, Drops to JPY 1,569.00",
        "link": "https://www.marketsmojo.com/news/stocks-in-action/astellas-pharma-stock-hits-day-low-amid-price-pressure-drops-to-jpy-156900-3659529",
        "imagepath": "https://i.marketsmojo.com/newsimg/2025/10/AstellasPharmaI_priceRelatedfactors_3659529.png",
        "date": "2025-10-30 20:18:08",
        "description": "Astellas Pharma, Inc. saw a significant stock decline today, contrasting with the modest decrease in the Japan Nikkei 225. Over the past year, Astellas has underperformed, with a notable drop compared to the index's gains. Despite challenges, the company shows strong management efficiency metrics."
      },
      {
        "title": "Astellas Pharma Stock Hits Day Low Amid Price Pressure, Drops 4.6%",
        "link": "https://www.marketsmojo.com/news/stocks-in-action/astellas-pharma-stock-hits-day-low-amid-price-pressure-drops-46-3623332",
        "imagepath": "https://i.marketsmojo.com/newsimg/2025/10/AstellasPharmaI_priceRelatedfactors_3623332.png",
        "date": "2025-10-15 18:21:23",
        "description": "Astellas Pharma, Inc. faced a significant stock decline today, contrasting with the broader market's performance. Over the past year, the company has seen a notable drop, despite a substantial increase in profits. Astellas maintains a strong EBIT to Interest ratio, reflecting its debt management capabilities."
      }
    ],
    "total": 3,
    "sid": "1130126",
    "stock_news_url": "https://www.marketsmojo.com/news/astellas-pharma-inc-1130126"
  },
  "announcements": "",
  "corporate_actions": {
    "msg": "No corporate action Found"
  }
}

News and Views

Astellas Pharma, Inc. Shows Strong Financial Growth Amidst Flat Performance

2025-11-11 16:16:05

Astellas Pharma, Inc. has reported its financial results for the quarter ending June 2025, revealing a mixed performance characterized by notable growth in key profit metrics despite an overall flat financial performance. The company's operating profit reached an impressive JPY 157,307 MM, marking the highest level recorded, with an operating profit margin of 31.1%. This indicates a strong operational efficiency and profitability for the company during this period.

In addition to the robust operating profit, Astellas Pharma, Inc. also reported significant growth in its pre-tax profit, which surged to JPY 92,009 MM, reflecting an impressive year-on-year growth rate of 89.45%. This substantial increase highlights the company's ability to enhance its profitability before tax considerations.

The net profit for the quarter also demonstrated remarkable growth, ...

Read More

Astellas Pharma Stock Hits Day Low Amid Price Pressure, Drops to JPY 1,569.00

2025-10-30 20:18:08

Astellas Pharma, Inc. saw a significant stock decline today, contrasting with the modest decrease in the Japan Nikkei 225. Over the past year, Astellas has underperformed, with a notable drop compared to the index's gains. Despite challenges, the company shows strong management efficiency metrics.

Read More

Astellas Pharma Stock Hits Day Low Amid Price Pressure, Drops 4.6%

2025-10-15 18:21:23

Astellas Pharma, Inc. faced a significant stock decline today, contrasting with the broader market's performance. Over the past year, the company has seen a notable drop, despite a substantial increase in profits. Astellas maintains a strong EBIT to Interest ratio, reflecting its debt management capabilities.

Read More

View All News